Quantifying the Lifetime Health and Societal Benefits from Earlier Diagnosis and Access to Approved Targeted Immunotherapies in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United States (P7-1.003)

Shamik Bhattacharyya; Annie Kennedy; Jeffrey Yu; Adrian Kielhorn; Foteini Tsotra; Diego Hernandez; Malina Müller

doi:10.1212/wnl.0000000000215587

June 9, 2026Neurology

Quantifying the Lifetime Health and Societal Benefits from Earlier Diagnosis and Access to Approved Targeted Immunotherapies in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United States (P7-1.003)

View at Publisher

Ask AI

Bookmark

Share

Key Points

To quantify the health and societal benefits of earlier diagnosis and access to targeted immunotherapies for AQP4-Ab+ NMOSD.
Utilized a cohort modeling approach to assess benefits.
Focused on patients with AQP4-Ab+ NMOSD in the United States.
Demonstrated substantial health benefits associated with earlier diagnosis.
Identified significant societal benefits from improved access to targeted immunotherapy.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Cohort modeling quantifies health and societal benefits of earlier diagnosis and targeted therapies in AQP4-Ab+ NMOSD, suggesting significant improvements.

Abstract

Quantify, using a cohort modeling approach, the health and societal benefits of earlier diagnosis and approved targeted immunotherapy access for AQP4-Ab+ NMOSD in the US.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bhattacharyya et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf32afaef96ed7f055ba4 https://doi.org/10.1212/wnl.0000000000215587

View at Publisher

Ask AI

Bookmark

Share

Quantifying the Lifetime Health and Societal Benefits from Earlier Diagnosis and Access to Approved Targeted Immunotherapies in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United States (P7-1.003)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Quantifying the Lifetime Health and Societal Benefits from Earlier Diagnosis and Access to Approved Targeted Immunotherapies in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United States (P7-1.003)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading